Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril (up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder

NCT00236054 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00236054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00236054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril (up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2004
Completion date
December 31, 2005
Enrollment
440
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety disorder